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Abstract
Background:  Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is a rationally designed
immunosuppressive drug. The current study investigates the effect of MMF on key pattern of restenosis in a cascade of
in vitro and ex vivo models.
Methods: Part I of the study investigated in northern blot and cytoflow studies the effect of MMF (50, 100, 150, 200,
250, and 300 µg/mL) on TNF-α  induced expression of intercellular adhesion molecule 1 (ICAM-1) in human coronary
endothelial cells (HCAEC) and human coronary medial smooth muscle cells (HCMSMC). Part II of the study applied a
human coronary 3D model of leukocyte attack, the 3DLA-model. HCAEC and HCMSMC were cultured on both sides
of a polycarbonate filters, mimicking the internal elastic membrane. Leukocyte attack (LA) was carried out by adding
human monocytes (MC) on the endothelial side. The effect of MMF (50 µg/mL) on adhesion and chemotaxis (0.5, 1, 2,
3, 4, 6, and 24 h after LA) and the effect on proliferation of co-cultured HCMSMC (24 h after LA) was studied. In part
III of the study a porcine coronary organ culture model of restenosis (POC-model) was used. After ex vivo ballooning
MMF (50 µg/mL) was added to the cultures for a period of 1, 2, 3, 4, 5, 6, and 7 days. The effect on reactive cell
proliferation and neointimal thickening was studied at day 7 and day 28 after ballooning.
Results: Expression of ICAM-1 in northern blot and cytoflow studies was neither clearly inhibited nor stimulated after
administration of MMF in the clinical relevant concentration of 50 µg/mL. In the 3DLA-model 50 µg/mL of MMF caused
a significant antiproliferative effect (p < 0.001) in co-cultured HCMSMC but had no effect on MC-adhesion and MC-
chemotaxis. In the ex vivo POC-model neighter reactive cell proliferation at day 7 nor neointimal hyperplasia at day 28
were significantly inhibited by MMF (50 µg/mL).
Conclusion: Thus, the data demonstrate a significant antiproliferative effect of clinical relevant levels of MMF (50 µg/
mL) in the 3DLA-model. The antiproliferative effect was a direct antiproliferative effect that was not triggered via
reduced expression of ICAM-1 or via an inhibition of MC-adhesion and chemotaxis. Probably due to technical limitations
(as e.g. the missing of perfusion) the antiproliferative effect of MMF (50 µg/mL) could not be reproduced in the coronary
organ culture model. A cascade of focused in vitro and ex vivo models may help to gather informations on drug effects
before large experimental studies are initiated.
Published: 12 May 2005
BMC Cardiovascular Disorders 2005, 5:9 doi:10.1186/1471-2261-5-9
Received: 17 December 2004
Accepted: 12 May 2005
This article is available from: http://www.biomedcentral.com/1471-2261/5/9
© 2005 Voisard et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2005, 5:9 http://www.biomedcentral.com/1471-2261/5/9
Page 2 of 11
(page number not for citation purposes)
Background
Stent coating with immunosuppressive or cytostatic
agents are valid advances in the struggle against restenosis
following coronary intervention. However these therapies
are hampered by high costs, especially in the case of mul-
tivessel disease. Moreover it is not entirely clear whether
restenosis is merely delayed and not inhibited [[1],
review]. Consequently the intense search for a systemic
approach to inhibit restenosis is required.
Restenosis is essentially characterized by migration and
proliferation of smooth muscle cells and extracellular
matrix accumulation. However, there is now increasing
evidence for a role of inflammation in the development of
restenosis. The underlying molecular mechanisms of rest-
enosis are, in fact, most probably regulated by inflamma-
tory mediators, such as cytokines [[2], review]. The
situation resembles to a certain degree to the activation of
the immune system during organ rejection. Therefore it is
not surprising that immunosuppressive agents are poten-
tial candidates in the treatment of restenosis.
Mycophenolate mofetil (MMF), the prodrug of mycophe-
nolic acid (MPA), is a rationally designed immunosup-
pressive drug. The active metabolite MPA is a selective,
non-competitive and reversible inhibitor of inosine
monophosphate dehydrogenase (IMPDH) and of the
type II isoform in particular [3]. The primary mechanism
of action of MPA is presumed to be anti-lymphoprolifera-
tive, a result of inhibition of inosine 5'-monophosphate
dehydrogenase (IMPDH), which is required for the de
novo synthesis of guanosine nucleotides which are neces-
sary for DNA and RNA synthesis and for lymphocytes to
proliferate maximally after stimulation [4]. Antiprolifera-
tive effects of MMF have been described in non-immune
cells [[5], review].
In the past data of animal studies could not be transferred
easily to the clinical situation due to species differences. In
the current study a cascade of human in vitro models in
combination with a porcine coronary ex vivo model is
applied to investigate the effects of MMF on key pattern of
restenosis. Unexpected or conflicting data can be analysed
before large experimental studies are initiated. Further-
more attention is focused on the relation between signifi-
cant inhibitory effects in vitro (SI) and maximal plasma
levels in vivo (MPL), the SI/MPL-ratio [6].
Central part of the current study is a 3D human coronary
transfilter co-culture model of leukocyte attack [7]. In this
model the effect of MMF on monocyte (MC) adhesion
and chemotaxis and reactive cell proliferation of co-cul-
tured smooth muscle cells (SMC) are investigated. In
order to obtain information on the effect of MMF on TNF-
alpha induced expression of adhesion molecules, the
effect on expression of ICAM-1 is studied in northern blot
and cytoflow studies. Finally MMF is added in a porcine
coronary organ culture model of restenosis for 1, 2, 3, 4,
5, 6, and 7 days and the effect on reactive cell proliferation
and neointimal hyperplasia is investigated.
Methods
Cell culture
Human coronary endothelial cells (HCAEC) and human
coronary smooth muscle cells (HCMSMC) were pur-
chased at Cambrex Bio Science (Vervier, B). HCAEC were
cultured in Endothelium Growth Medium (Cambrex) and
identified by the typical "cobble stone" growth pattern
and positive reaction against von Willebrand factor
(Dakopatts). HCMSMC were grown in Smooth Muscle
Cell Growth Medium (Cambrex). For identification of
HCMSMC antibodies against smooth muscle α -actin
(Renner, Darmstadt, D) were used. Human MC were iso-
lated from the residual leukocytes of single donors using
MACS cell-isolation kit (Milteny Biotec GmbH).
Mycophenolate Mofetil
Mycophenolate mofetil (MMF): Cellcept®, Roche, Basel,
CH, 0.005 – 500 µg/mL, dilution: aqua ad inject., MPL: 34
µg/mL [8].
RNA extraction and Northern blot analysis
For Northern blot studies of the effect of MMF/TNF-α
treatment on expression of ICAM-1, monocultures of
HCAECs and HCMSMCs were incubated with MMF (50,
100, 150, 200, 250, and 300 µg/mL) for a period of 18 hrs.
During the last 6 hrs of MMF incubation, expression of
adhesion molecules was stimulated by adding of TNF-α
(20 ng/mL). Total RNA (3 × 106 cells) was isolated with
RNEasy Mini Kit (Qiagen), and 10 µg of RNA was used in
standard Northern blot analysis with an ICAM-1 probe.
A non radioactive labelling and detection system (Amer-
sham Biosciences Europe GmbH, Freiburg, D) was used to
detect the relative band density of ICAM-1 mRNA in com-
parison with TNF-α -stimulated cells. GAPDH was used as
a control. Experiments were performed in triplicate.
Flow cytometry
For flow cytometry analysis of the expression of ICAM-1
in HCAEC and HCMSMC cells were trypsinized and
seeded into 6-well dishes (5 × 104 cells). MMF (50, 100,
150, 200, 250, and 300 µg/mL) was added to the cultures
for a period of 18 hrs. During the last 6 hrs of MMF incu-
bation, the expression of adhesion molecules was stimu-
lated by adding of TNF-α  (20 ng/mL).
After MMF/TNF-α  treatment, cells were washed twice with
phosphate-buffered saline (pH 7.2) and trypsinized. Cells
were resuspended in 100 µL of a FITC-conjugatedBMC Cardiovascular Disorders 2005, 5:9 http://www.biomedcentral.com/1471-2261/5/9
Page 3 of 11
(page number not for citation purposes)
monoclonal antibody directed against ICAM-1 (clone
84H10, Dianova Immunotech; final concentration 10 µg/
mL) and incubated for 20 min at 4°C. A total of 1 × 104
cells (100% gated) were analyzed immediately with a
flowcytometer (BDFACsCalibur, Durchflußzytometer
Becton Dickinson, Heidelberg, D).
The effects of MMF (50 µg/mL – 300 µg/mL) on vitality of
HCAEC and HCMSMC were analyzed with propidium
iodide (Sigma-Aldrich, Taufkirchen, D).
The 3DLA model
Three-dimensional human coronary units of leukocyte
attack (3DLA units) mimic the inner layers of human cor-
onary arteries [7]. The internal elastic membrane is repre-
sented by a polycarbonate filter with a thickness of 10 µm
and a pore size of 5 µm (Whatman, Göttingen, D). Filters
were fixed in a specially designed frame and inserted in a
siliconized culture dish. On both sides of the filters cell
cultures were established, direct contact of the cultures
was made possible through the pores of the filter.
HCMSMC were seeded on one side of the filter at a density
of 2.5 × 104 cells / cm2. After 24 h cells had attached to the
surface and frame and filters were turned upside down.
HCAEC were seeded on the opposite side of the filter at a
density of 2.5 × 104  cells / cm2. Both HCAEC- and
HCMSMC-cultures were supplied with the appropriate
culture medium and cultured for 14 days.
At day 14, 3DLA-units were incubated with MMF (50 µg/
mL) for 18 h. During the last 6 h of MMF incubation, the
models were treated with TNF-α  (20 ng/mL). For leuko-
cyte attack, the required numbers of MC was calculated in
relation to the relative concentration of MC in the full
human blood [7]. 3 × 105  MC were seeded on the
endothelial side of the 3DLA-units. The effect of MMF on
MC-adhesion and MC-chemotaxis was studied at 30 min,
1, 2, 3, 4, 6, and 24 h after leukocyte attack; the effect on
proliferation of co-cultured HCMSMC was investigated 24
h after leukocyte attack. Controls were performed without
MMF-treatment. [for detailed information: [7]].
The porcine coronary organ culture model
Fresh hearts of 12 pigs, ranging in age from 3 to 5 months,
weighing 100 to 120 kg, were obtained from a local
slaughterhouse. In the laboratory, the left anterior
descending coronary artery (LAD) was carefully prepared.
Section were made at 4 mm intervals perpendicular to the
vessel wall axis [9].
Ex vivo ballooning and adding of MMF
For ex vivo angioplasty the prepared LAD segments were
placed over a 3 mm balloon catheter (Medtronic
14K2030E, Medtronic, Kerkrade, North Carolina, USA)
and were treated with 9 bar for a period of 60 s. After ex
vivo ballooning MMF (50 µg/mL) was added to the cul-
tures for a period of 1, 2, 3, 4, 5, 6, and 7 days. At each
medium exchange the drug was renewed.
Cultivation and fixation of coronary organ cultures
After ballooning the segments were transferred to six-well
plates (Tecnomara, Fernwald, D) and cultured in a mix-
ture of Waymouth's MB 752/1 and Ham F12 nutrient
mixture (1:1; vol/vol; Cambrex) supplemented with 15%
fetal calf serum (Cambrex) at 37°C in 5% carbon dioxide.
Organ cultures were cultured for 7 and 28 days, culture
medium was exchanged every second or third day. Cul-
ture conditions for control groups were exactly the same
as described for the angioplasty/MMF group.
Analysis of reactive cell proliferation and neointimal thickening
The effect of MMF (50 µg/mL) on reactive cell prolifera-
tion and neointimal thickening was studied at day 7 and
day 28 after ballooning, controls were performed with
and without ballooning [for detailed information: [9]].
Statistical analysis
Data of northern blot and flow cytometry studies were
presented as mean ± S.D. Statistical significance of differ-
ences between controls and drug-treated cells was deter-
mined by paired Student's t-test. The Mann-Whitney rank-
sum test was used to investigate the significance of differ-
ences in the 3DLA-model and the organ culture model.
Statistical significance was accepted for P < 0.05.
Results
Identification of cells
In monocultures of HCAECs cells were identified by a
positive reaction with antibodies directed against von Wil-
lebrand factor and by the typical "cobblestone" growth
pattern in culture. Monocultures of HCMSMC exhibited
the "hill and valley" growth pattern and reacted positively
with antibodies against smooth muscle α -actin.
Effect of MMF on ICAM-1 mRNA levels: Northern blot 
studies
After TNF-α  stimulus, band density of mRNA ICAM-1 in
HCAEC was increased 30-fold, which corresponds to a rel-
ative band density of 100% (Fig. 1). After incubation of
HCAEC with MMF in concentrations of 50, 100, 150, 200,
and 250 µg/ml expression of ICAM-1 was further
increased by 23.92% (p = 0.01), 29.51% (n.s.), 75.87%
(n.s.), 79% (n.s.), and 24.34% (n.s.). MMF in a concentra-
tion of 300 µg/mL caused an inhibition of ICAM-1 expres-
sion by 40.57% (n.s.).
In HCMSMC, band density of mRNA ICAM-1 was
increased 7.5-fold after TNF-α -stimulus, relative band
density was increased from 13.4% to 100% (n.s.).BMC Cardiovascular Disorders 2005, 5:9 http://www.biomedcentral.com/1471-2261/5/9
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Northern blots and relative band densities of TNF-α -induced expression of ICAM-1 mRNA after incubation of HCAECs and  HCMSMCs with 50, 100, 150, 200, 250, and 300 µg/mL of MMF Figure 1
Northern blots and relative band densities of TNF-α -induced expression of ICAM-1 mRNA after incubation of HCAECs and 
HCMSMCs with 50, 100, 150, 200, 250, and 300 µg/mL of MMF.
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Incubation with MMF in the concentration of 50 µg/mL
caused a slight inhibitory effect on band density of mRNA
ICAM-1 by 12.02% (n.s.). After incubation of HCMSMC
with MMF in concentrations of 100, 150, 200, 250, and
300 µg/mL relative band density of ICAM-1 was increased
by 59.9% (n.s.), 70.61% (n.s.), 68.7% (n.s.), 67.8% (n.s.),
and 69.4% (n.s.).
Both in HCAEC and HCMSMC, expression of GAPDH
after adding of MMF in concentrations of 50, 100, 150,
200, and 250 µg/ml was identical with untreated controls.
Effect of MMF on ICAM-1: Flow cytometry studies
The effects of MMF (50, 100, 150, 200, 250, and 300 µg/
mL) on the TNF-α  induced expression of ICAM-1 are
demonstrated in Figure 2. A dose dependent significant
inhibition of ICAM-1 expression was detected in HCAEC.
No significant effect was seen in HCMSMC.
In HCAEC, treatment with TNF-α  increased the mean flu-
orescence levels (%) of ICAM-1 expression 10.5-fold from
9.48% to 100.00%. Incubation of HCAEC with MMF
caused a dose dependent inhibition of ICAM-1 expres-
sion. After incubation with MMF in concentrations of 50,
100, and 150 µg/mL expression of ICAM-1 was signifi-
cantly decreased by 18.57%, 26.46%, and 37.92% (p <
0.05, p < 0.01, p < 0.05). Incubation with 200, 250, and
300 µg/mL caused an decrease by 83.77%, 92.41%, and
93.17% (p < 0.01, p < 0.001, p < 0.001).
Graphics and histograms (cytoflow data) of the effect of MMF (50, 100, 150, 200, 250, and 300 µg/mL) on TNF-α -induced  expression of ICAM-1 in HCAECs (A, B) and HCMSMCs (C, D) after 18 h Figure 2
Graphics and histograms (cytoflow data) of the effect of MMF (50, 100, 150, 200, 250, and 300 µg/mL) on TNF-α -induced 
expression of ICAM-1 in HCAECs (A, B) and HCMSMCs (C, D) after 18 h. Negative control (dotted line) and ICAM-1 expres-
sion in untreated cells (grey line) are included.
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In HCMSMC a very weak inhibition of ICAM-1 expression
was detected without statistical significance. After incuba-
tion of HCMSMC with MMF in concentrations of 50, 100,
150, and 200 µg/mL no inhibitory effect on ICAM-1
expression was detected. MMF in concentrations of 250
and 300 µg/mL caused a 9.03% (n.s.) and 16.68% (n.s.)
inhibition of ICAM-1 expression.
In HCAEC no toxic effects were detected after adding of
MMF in concentrations of 50 µg/ml, 100 µg/ml, and 150
µg/ml, little toxic effects were found after adding of MMF
in concentrations of 200 µg/ml, 250 µg/ml, and 300 µg/
ml. In HCMSMC no toxic effects were detected after add-
ing of MMF in concentration of 50 µg/ml – 300 µg/ml.
3DLA-Model: Effect of MMF on monocyte adhesion, 
chemotaxis, and proliferation of human coronary smooth 
muscle cells
In 3DLA units the effect of MMF in a concentration of 50
µg/mL on monocyte adhesion, chemotaxis, and prolifera-
tion of HCMSMC was studied. 3DLA-units were success-
fully established (Fig. 3). On the endothelial side of the
units one to two layers of cells were found. The superficial
layer of these cells was composed of HCAEC, as identified
by positive reaction with antibodies directed against von
Willebrand factor. On the HCMSMC side of the units,
three to five layers of cells with the typical hill and valley
growth pattern were observed.
(A) Effect of MMF (50 µg/mL) on monocyte adhesion after leukocyte attack on the endothelial side of the human coronary  transfilter co-culture model (3DLA units) Figure 3
(A) Effect of MMF (50 µg/mL) on monocyte adhesion after leukocyte attack on the endothelial side of the human coronary 
transfilter co-culture model (3DLA units). (B) Effect of MMF (50 µg/mL) on monocyte chemotaxis after leukocyte attack on the 
endothelial side of the human coronary transfilter co-culture model (3DLA units). (C) Identification of monocytes by positive 
staining against CD68 (arrow).
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Human monocytes were isolated from the residual leuko-
cytes of single donors and identified by positive reaction
with antibodies directed against CD68. A 93% purity of
monocyte preparations was determined by flow
cytometry.
Adhesion of MC was slightly stimulated 0.5, 1, 2, 3, 4 and
6 h after leukocyte attack in MMF-treated 3DLA-units (Fig.
3A and 3C). In comparison to 3DLA-units without MMF
treatment the stimulatory effect was 12.6% (n.s.), 31.5%
(p < 0.05), 29.2% (p < 0.05), 33.2% (n.s.), 24.9% (n.s.),
and 64,1% (p = 0.002). 24 h after leukocyte attack a very
small inhibitory effect of MMF by 8.1% (n.s.) was
detected.
Chemotaxis of MC from the endothelial side of the model
to the HCMSMC side of the model was very little, both
with and without MMF-treatment (Fig. 3B).
Proliferation of HCMSMC in the transfilter co-culture
units was significantly inhibited by MMF (50 µg/ml) by
more than 90% (Fig. 4A and 4B). Proliferation of
HCMSMC in the 3DLA-units after TNF-α  stimulus was sig-
nificantly stimulated by 103% (p < 0.001) in comparison
to untreated controls. Adding of MMF in a concentration
of 50 µg/mL significantly inhibited proliferation of
HCMSMC by 95.5% (p < 0.001). The inhibitory effect was
not influenced by TNF-α . In the transfilter co-culture units
without TNF-α  the inhibitory effect in comparison to con-
trol was 93.4% (p < 0.001).
(A) Effect of MMF (50 µg/mL) on proliferative activity of co-cultured HCMSMC after leukocyte attack with monocytes on the  endothelial side of TNF-α -stimulated 3DLA units Figure 4
(A) Effect of MMF (50 µg/mL) on proliferative activity of co-cultured HCMSMC after leukocyte attack with monocytes on the 
endothelial side of TNF-α -stimulated 3DLA units. (B) Proliferation of smooth muscle cell demonstrated by positive staining of 
against BrdU (arrow). F = Filter, *** = p < 0.001.
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Coronary Organ Culture-Model: Effect of MMF on cell 
proliferation and neointimal proliferation after ex vivo 
ballooning
The effects of ex vivo ballooning in the porcine organ cul-
ture model have been recently characterized by our group
(9). Maximal reactive cell proliferation was detected at
day 7, maximal reactive neointimal hyperplasia was
found at day 28. In the current study the effect of a 1, 2, 3,
4, 5, 6, and 7 days incubation with MMF (50 µg/mL) on
reactive cell proliferation (Fig. 5) and neointimal hyper-
plasia was studied 7 (Fig. 6A) and 28 days (Fig. 6B) after
ex vivo ballooning. No clear inhibitory or stimulatory
effect was detected.
At day 7 neointimal cell proliferation was slightly
increased (n.s.) in comparison to untreated controls. Add-
ing of MMF for 1, 3, and 5 days did not exhibit an effect
on cell proliferation. A stimulatory effect was found after
adding of MMF for a period of 2 and 6 days, an inhibitory
effect was seen after adding of MMF for a period of 4 and
7 days. 28 days after ballooning cell proliferation in the
POC-model was very low, both in untreated controls and
after treatment with MMF. Almost no cell proliferation
was detected in the media.
At day 7 after ex vivo ballooning neointimal hyperplasia
was very low in comparison to controls. No neointimal
hyperplasia was detected after adding of MMF for 1, 2, 4,
and 6 days, an inhibitory effect on neointimal hyperplasia
was seen after adding of MMF for a period of 3, 5, and 7
days. 28 days after ex vivo ballooning neointimal hyper-
plasia was increased by 809% (n.s.). Adding of MMF for a
period of 1, 2, 3, 4, and 7 days caused an increase of
neointimal thickening by 108.9%, 144%, 51.8%, 104.9%,
Effect of a 1–7 days treatment with MMF (50 µg/mL) on reactive cell proliferation in balloon-injured porcine coronary organ  cultures at day 7 (A) and day 28 (B) Figure 5
Effect of a 1–7 days treatment with MMF (50 µg/mL) on reactive cell proliferation in balloon-injured porcine coronary organ 
cultures at day 7 (A) and day 28 (B). C = control, CB = control ballooning. Positive staining against BrdU (arrow) in the bal-
looning control group (C).
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and 4.5%. Adding of MMF for a period of 5 and 6 days
decreased neointimal hyperplasia by 9.2% and 7.7%. Due
to high standard deviations statistical significance was not
achieved.
Discussion
The present study employes a cascade of in vitro and ex
vivo models to investigate the effect of MMF on key proc-
esses of coronary restenosis. Three basic conclusions of
the study were determined. First, therapeutical concentra-
tions of MMF exhibit a significant antiproliferative effect
in HCMSMC. Second, this antiproliferative effect was not
triggered via inhibition of adhesion and chemotaxis of
MC or reduced expression of ICAM-1 on mRNA or protein
levels. Third, a significant antiproliferative effect of MMF
could not be reproduced in the porcine coronary ex vivo
model.
MPA, a product of Penicillium fungus, was originally iso-
lated in 1896, and shown to have anti-neoplastic, anti-
viral, anti-fungal and immunosuppressive activity. MMF
is the semi-synthetic morpholinoethyl ester of MPA. After
oral administration and absorbtion of MMF, the ester
linkage is rapidly hydrolyzed by esterases to yield MPA,
the active immunosuppressive agent. The bioavailability
of oral MPA from MMF is 96% and the maximum of
plasma concentration occurs about 2 h after administra-
tion [[10], review]. Over 10 years ago, MMF was first
shown to prolong organ allograft survival [11]. Additional
early studies demonstrated that MMF prevents acute rejec-
tion, reverses acute rejection and increases graft survival in
several species and in different animal transplantation
studies. Shortly thereafter, the first human renal allograft
recipients were treated with MMF [[12], review]. Although
many data exist on MMF in organ transplantation, data of
Effect of a 1–7 days treatment with MMF (50 µg/mL) on reactive neointimal hyperplasia in balloon-injured porcine coronary  organ cultures at day 7 and day day 28 Figure 6
Effect of a 1–7 days treatment with MMF (50 µg/mL) on reactive neointimal hyperplasia in balloon-injured porcine coronary 
organ cultures at day 7 and day day 28. C = control, CB = control ballooning. Elastica van Gieson-staining in the ballooning 
control group (C).
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the effect of MMF in experimental models of atherosclero-
sis and restenosis are very limited [13,14].
The group of Fraser-Smith [13] demonstrated that orally
administered MMF inhibits restenosis after carotid injury
in a rat model and Raisanen-Sokolowski et al. [14]
reported that MMF inhibits inflammation and SMC pro-
liferation in a rat aortic allograft model. In these studies
the relation between the significant in vitro respectively
experimental effect (SI) and the maximal plasma level
(MPL), the SI/MPL-ratio [6] was smaller than one, indicat-
ing an at least theoretical clinical relevance of the data.
Recently the antiproliferative properties of MMF in non-
immune cells have been summarized in a valuable review
[5]. Gregory et al. [15] reported that human aortic smooth
muscle cell proliferation was significantly reduced by
MMF in the presence of angiotensin II or β -FGF and
Mohacsi et al. [16] demonstrated that MMF potently
inhibited rat and human aortic smooth muscle cell
proliferation.
In accordance with these reports the current study demon-
strates a significant inhibition of HCMSMC-proliferation
after incubation with 50 µg/mL of MMF in the 3DLA-
model. The SI/MPL-ratio [6] of 1.47 indicates that this
concentration is merely slightly above systemic plasma
levels of MMF. The complexity of the 3DLA-model allows
studies of HCMSMC-proliferation and MC-adhesion and
MC-chemotaxis in one model. Although an inhibitory
effect of MMF on CD4/CD8-lymphocyte proliferation is
described in the literature and an inhibitory effect on MC-
adhesion and chemotaxis might have been expected with
reference to the clinical successes of the agent in the ther-
apy of acute organ rejection [11], no inhibitory effect on
MC-adhesion and MC-chemotaxis was detected in the
3DLA-model. An inhibitory effect on MC-adhesion and
chemotaxis would have been of importance due to the
fact that during the first 24 h after leukocyte attack mono-
cytes seem to play a predominant role in comparison to
CD4/CD8-lymphocyte attack, as recently demonstrated
by our group [7]. The data indicate that the strong antipro-
liferative effect of MMF was not triggered via an inhibitory
effect on MC.adhesion or chemotaxis.
It has been reported that MMF inhibited the induced
expression of adhesion molecules on endothelial cells
measured by marked antibodies and scanning fluorimetry
[17]. On the other hand the group of Raab et al. [18] dem-
onstrated that MMF in a concentration 10 µM (corre-
sponding to 3.2 µg/mL) does not inhibit TNF-α -induced
stimulation of ICAM-1 in HUVEC. In the current study
conflicting data are reported on mRNA and protein levels.
Although in northern blot studies a stimulatory effect of
MMF on TNF-α -induced expression of ICAM-1 was found,
a dose dependent inhibitory effect was detected in flow
cytometry studies. Due to the fact that littly toxic effects
were found after incubation of HCAEC with MMF in con-
centrations of 200 µg/ml – 300 µg/ml, the decrease of
ICAM-1 protein levels in HCAEC may be partially
explained by these toxic effects. Clinically relevant con-
centrations of MMF (50 µg/mL) however neighter stimu-
lated nor inhibited expression of ICAM-1. If a
concentration of 50 µg/mL of MMF is considered the data
are in accordance with the reports of Raab et al. [18]. Due
to the fact that MMF (50 µg/mL) did not inhibit expres-
sion of ICAM-1 on mRNA- and protein levels and exhib-
ited no effect on MC-adhesion and MC-chemotaxis, the
described antiproliferative effect of MMF eighter a direct
one or it was triggered via other pathways not investigated
in the current study.
With the hypothesis of a direct antiproliferative effect
MMF (50 µg/mL) was studied in the coronary porcine
organ culture system of restenosis, the POC-model [9]. In
the POC-model we have previously described a maximal
reactive cell proliferation at day 7 and a maximal reactive
neointimal hyperplasia at day 28. In order to get informa-
tion on the period of time needed to treat MMF was added
for a period of 1, 2, 3, 4, 5, 6, and 7 days, the time span
between angioplasty and the peak of reactive cell prolifer-
ation. In the POC-model reactive cell proliferation was
inhibited after adding of MMF for a period of 4 days and
7 days, no inhibitory effect on neointimal hyperplasia was
detected. These results are in accordance with the data of
the experimental models applied by Fraser-Smith et al.
[13] and Raisanen-Sokolowski et al. [14], describing an
antiproliferative effect of an about 5-times increased con-
centration of MMF. Surprisingly in the current study no
antiproliferative effect was detected after adding MMF for
a period of 5 days and 6 days. Due to the fact that the ester
linkage of MMF is rapidly hydrolysed in the plasma to
MPA [10], it can be excluded that an inactive form of MMF
caused the missing inhibitory effect. However high stand-
ard deviations and the absence of perfusion in the model
may have contributed to the negative effect. In the pre-
sented coronary ex vivo model of restenosis [9,19] the
solved drug gets into contact with the adventitial side, the
endothelial side, and both frontal sides of the artery seg-
ment. Therefore our group has reported earlier that the
model mimics a simultaneous intra/extravascular drug
administration [19]. However due to the absence of per-
fusion the contact between the endothelial side of the
artery segments and the culture medium is limited. Lim-
ited nutrition of this area may be critical because balloon-
ing injury and reactive cell proliferation&neointimal
hyperplasia are expected to occure predominantly in this
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Conclusion
The current data demonstrate a significant antiprolifera-
tive effect of MMF in concentrations close to the systemic
plasma level (SI/MPL-ratio: 1.47). The effect was not trig-
gered via inhibitory effects on expression of ICAM-1 or via
inhibitory effects on MC-adhesion and MC-chemotaxis.
Eighter the effect was a direct antiproliferative effect or it
was triggered via pathways not investigated in the present
study. Probably due to technical limitations (as e.g. the
missing of perfusion) the antiproliferative effect of MMF
(50  µg/mL) could not be reproduced in the coronary
organ culture model. A cascade of focused in vitro and ex
vivo models may help to gather informations on drug
effects before large experimental studies are initiated.
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